Table of Contents
NU670 Psychopharmacology and Health promotion
Neurotransmitter Chart (Unit 2)
Antipsychotics Chart (Unit 7)
Antidepressants, Anxiolytics, & Mood Stabilizers Chart (Units 5, 6)
Substance Use Resources (Chart links) (Units 11, 13, 14)
Additional Resources List
Neurotransmitters Chart | |||||||
Function (Excitatory or Inhibitory) | Locations | Receptors | Effects of Deficient | Effects of Surplus | Agonist Drug | Antagonist Drug | |
Acetylcholine |
|
||||||
Dopamine |
|
||||||
Endorphins |
|
||||||
GABA |
|
||||||
Glutamate |
|
||||||
Glycine |
|
||||||
Glutamate |
|
||||||
Norepinephrine |
|
||||||
Serotonin |
|
Notes:
Antipsychotics | ||||||||||||||
First Generation | Side Effects (L=Low, M=Moderate, H=High) | |||||||||||||
Generic Name | Trade Name | Route(s) of Administration | LAI option | Starting Dose | Half Life | Indications (s/sx & diagnosis) | MOA (neurotransmitter effects) | EPS | Hyperlipidemia | T2DM | Weight Gain | Cognitive Issue | Other SE | Costs |
Second Generation | ||||||||||||||
Notes:
Antidepressants, Anxiolytics & Mood Stabilizers | ||||||||||||||
Antidepressants | Side Effects (L=Low, M=Moderate, H=High) | |||||||||||||
Generic Name | Trade Name | Route(s) of Administration | LAI option | Starting Dose | Half Life | Indications (s/sx & diagnosis) | MOA (neurotransmitter effects) | EPS | Hyperlipidemia | T2DM | Weight Gain | Cognitive Issue | Other SE | Costs |
SSRIs | ||||||||||||||
SNRIs | ||||||||||||||
TCAs | ||||||||||||||
MAOIs | ||||||||||||||
Atypical | ||||||||||||||
Anxiolytics | ||||||||||||||
Benzodiazepines | ||||||||||||||
Barbiturates | ||||||||||||||
Mood Stabilizers | ||||||||||||||